Invention Grant
- Patent Title: Tumor-selective CTLA-4 antagonists
-
Application No.: US16559561Application Date: 2019-09-03
-
Publication No.: US11279752B2Publication Date: 2022-03-22
- Inventor: John C. Williams , Ulrich Rodeck , Kurt Jenkins
- Applicant: City of Hope , Thomas Jefferson University
- Applicant Address: US CA Duarte; US PA Philadelphia
- Assignee: City of Hope,Thomas Jefferson University
- Current Assignee: City of Hope,Thomas Jefferson University
- Current Assignee Address: US CA Duarte; US PA Philadelphia
- Agency: Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
- Main IPC: C07K14/82
- IPC: C07K14/82 ; C07K16/28 ; C07K14/47 ; C07K14/705 ; C07K14/71 ; C12N9/64
Abstract:
Provided herein are recombinant masking proteins and recombinant ligand proteins useful in treating cancer, neurodegenerative disease, and cardiovascular disease. The recombinant masking proteins provided herein may, inter alia, be used as non-covalent masks of antagonists of, for example, cellular growth factors (e.g., TNF) or cell surface proteins (e.g., CTLA-4).
Public/Granted literature
- US20200325212A1 TUMOR-SELECTIVE CTLA-4 ANTAGONISTS Public/Granted day:2020-10-15
Information query
